Literature DB >> 8254086

Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma.

M Martinazzi1, F Crivelli, C Zampatti, S Martinazzi.   

Abstract

AIMS: To determine the immunohistochemical expression of epidermal growth factor receptor (EGF-R) in high grade, intermediate, and low grade tumours.
METHODS: Specimens from 931 breast carcinomas were partly formalin fixed and paraffin wax embedded, to classify cases, and partly frozen in liquid nitrogen, cryostat sectioned, and immunostained using two monoclonal antibodies from clone 455 and 528 to demonstrate EGF-R positive cells. An avidin-biotin complex and peroxidase method was used after incubation with biotinylated anti-mouse antibody; colour was developed using a diaiminobenzidine solution.
RESULTS: Low grade carcinomas seldom expressed EGF-R (n = 3) compared with 106 high grade infiltrating ductal carcinomas: EGF-R positive cases were much less common in infiltrating lobular than in infiltrating ductal carcinoma. Medullary carcinomas did not differ from infiltrating ductal carcinomas.
CONCLUSIONS: The very low incidence of EGF-R positive cases in the "special type" group of breast carcinomas with a good prognosis is in line with the absence of the homologous c-erbB-2 and p53 oncoproteins, and the rarity of highly proliferating and oestrogen/progesterone negative cases. EGF-R expression in infiltrating lobular carcinoma was in keeping with the intermediate behaviour of this kind of tumour. EGF-R expression in cases of pure medullary carcinoma is the same as that of high grade tumours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254086      PMCID: PMC501683          DOI: 10.1136/jcp.46.11.1009

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; P Price; A McKinna; S Harrison
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

3.  c-erbB-2 expression in different histological types of invasive breast carcinoma.

Authors:  S Soomro; S Shousha; P Taylor; H M Shepard; M Feldmann
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

4.  Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears.

Authors:  V Kuenen-Boumeester; T H Van Der Kwast; H A Van Laarhoven; S C Henzen-Logmans
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

5.  Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

Authors:  J R Sainsbury; J R Farndon; G K Needham; A J Malcolm; A L Harris
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

6.  Alveolar variant of invasive lobular carcinoma of the breast. A tumor rich in estrogen receptors.

Authors:  S Shousha; C M Backhous; J Alaghband-Zadeh; I Burn
Journal:  Am J Clin Pathol       Date:  1986-01       Impact factor: 2.493

7.  Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion.

Authors:  M Toi; Y Hamada; T Nakamura; H Mukaida; S Suehiro; T Wada; T Toge; M Niimoto; T Hattori
Journal:  Int J Cancer       Date:  1989-02-15       Impact factor: 7.396

  7 in total
  6 in total

1.  Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands.

Authors:  P M Peiris; F He; G Covarrubias; S Raghunathan; O Turan; M Lorkowski; B Gnanasambandam; C Wu; W P Schiemann; E Karathanasis
Journal:  Nanoscale       Date:  2018-04-19       Impact factor: 7.790

Review 2.  EGFR signaling in breast cancer: bad to the bone.

Authors:  John Foley; Nicole K Nickerson; Seungyoon Nam; Kah Tan Allen; Jennifer L Gilmore; Kenneth P Nephew; David J Riese
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

3.  Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer.

Authors:  Georgios Lazaridis; Sofia Lambaki; Georgia Karayannopoulou; Anastasia G Eleftheraki; Irene Papaspirou; Mattheos Bobos; Ioannis Efstratiou; George Pentheroudakis; Nikolaos Zamboglou; George Fountzilas
Journal:  Strahlenther Onkol       Date:  2014-07       Impact factor: 3.621

4.  A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Authors:  Achim A Jungbluth; Elisabeth Stockert; H J Su Huang; Vincent P Collins; Keren Coplan; Kristin Iversen; Denise Kolb; Terrance J Johns; Andrew M Scott; William J Gullick; Gerd Ritter; Leonard Cohen; Matthew J Scanlan; Webster K Cavenee; Lloyd J Old; Webster K Cavanee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-06       Impact factor: 11.205

5.  Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.

Authors:  S Samanta; V M Sharma; A Khan; A M Mercurio
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

6.  Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer.

Authors:  Yiqing Tang; Li Zhu; Yafen Li; Jun Ji; Jianfang Li; Fei Yuan; Dengbin Wang; Weiguo Chen; Ou Huang; Xiaosong Chen; Jiayi Wu; Kunwei Shen; Wings T Y Loo; Louis W C Chow
Journal:  J Transl Med       Date:  2012-09-19       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.